Intuitive Surgical (ISRG) showcased robust growth in Q3 2025 earnings, leading to a surge in stock prices and endorsements from analysts and investors alike. Celebrated market expert Jim Cramer expressed his support for ISRG amid its impressive performance. The earnings surge was majorly attributed to drafting demand for ISRG's
da Vinci 5 robotic procedures, which led to a significant increase in the firm's revenues. Owing to this, multiple sector voices continued to view ISRG as a solid buy, despite the post-earnings stock surge.
UBS and RBS Capital retained their neutral and buy ratings, respectively, with ISRG remaining attractive due to its solid leadership and innovative advancements. Intuitive's stock further gained after FDA's clearance for its AI technology, cementing its place as an industry leader. The
strong Q3 results also resulted in a 27% return from the stocks, making ISRG one of the most popular choices in the market. Despite the expensive valuation, the continued growth, buy-back schemes, and AI system upgrades further underlined the potential for future growth. As ISRG is navigating the tides impressively, it remains a lucrative pick for both short-term gains and long-term investments.
Intuitive Surgical ISRG News Analytics from Wed, 10 Sep 2025 07:00:00 GMT to Sat, 25 Oct 2025 15:26:45 GMT -
Rating 8
- Innovation 8
- Rumor -5
